Led · Series A · May 2021

Mindera Health develops and commercializes next-generation medical technology to enable a new era of skin analytics at the molecular level. Its flagship product, Mind.Px™, is designed to prospectively predict a patient’s response to biologic drug classes prior to therapeutic selection and treatment. The platform uses a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample and combines next-generation sequencing with machine learning to generate clinically validated data. Mindera operates a CLIA- and CAP-certified laboratory and holds ISO 13485:2016 certification. The company is actively commercializing Mind.Px™ and is using recent financing to support continued commercialization. Ron Rocca is the company’s CEO. Mindera Corporation, based in San Diego, develops and commercializes next-generation medical technology to enable skin analytics at the molecular level. Its core technology combines a proprietary dermal biomarker patch with next-generation sequencing (NGS) and machine learning to generate clinically validated data. The company says its data can reduce healthcare system costs and improve patient outcomes. Mindera intends to commercialize Mind.Px, a tool to prospectively predict patient response to expensive psoriasis biologics, and to continue development of the Mindera Dermal Intelligence Platform. The company operates a CLIA- and ISO 13485-certified laboratory. It raised $12.6M in a Series A-2 to fund commercialization and platform development.